🚀 VC round data is live in beta, check it out!

Genxone Valuation Multiples

Discover revenue and EBITDA valuation multiples for Genxone and similar public comparables like Aton, Modus Therapeutics, Instituto Rosenbusch, Akari Therapeutics and more.

Genxone Overview

About Genxone

Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.


Founded

2016

HQ

Poland

Employees

N/A

Website

genxone.eu

Financials (FY)

Revenue: $653K
EBITDA: ($308K)

EV

$5M

Valuation Multiples

Multiples.vc

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Genxone Financials

Genxone reported last fiscal year revenue of $653K and negative EBITDA of ($308K).

In the same fiscal year, Genxone generated $359K in gross profit, ($308K) in EBITDA losses, and had net loss of ($597K).


Genxone P&L

In the most recent fiscal year, Genxone reported revenue of $653K and EBITDA of ($308K).

Genxone expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Genxone forward-looking valuation multiples
LTMNTMLast FYFY 2026FY 2027FY 2028
RevenueXXX$653KXXXXXXXXX
Gross ProfitXXX$359KXXXXXXXXX
Gross MarginXXX55%XXXXXXXXX
EBITDAXXX($308K)XXXXXXXXX
EBITDA MarginXXX(47%)XXXXXXXXX
EBIT MarginXXX(103%)XXXXXXXXX
Net ProfitXXX($597K)XXXXXXXXX
Net MarginXXX(92%)XXXXXXXXX

Financial data powered by Morningstar, Inc.

Genxone Stock Performance

Genxone has current market cap of $6M, and enterprise value of $5M.

Market Cap Evolution


Genxone's stock price is $1.75.

See Genxone trading valuation data
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$5M$6M0.1%XXXXXXXXX$-0.18

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Genxone Valuation Multiples

Genxone trades at 7.4x EV/Revenue multiple, and (15.7x) EV/EBITDA.

See valuation multiples for Genxone and 15K+ public comps

Genxone Financial Valuation Multiples

As of April 19, 2026, Genxone has market cap of $6M and EV of $5M.

Equity research analysts estimate Genxone's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Genxone has a P/E ratio of (9.7x).

LTMNTMLast FYFY 2026FY 2027FY 2028
Market cap (current)$6MXXX$6MXXXXXXXXX
EV (current)$5MXXX$5MXXXXXXXXX
EV/RevenueXXX7.4xXXXXXXXXX
EV/EBITDAXXX(15.7x)XXXXXXXXX
EV/EBITXXX(7.2x)XXXXXXXXX
EV/Gross ProfitXXX13.5xXXXXXXXXX
P/EXXX(9.7x)XXXXXXXXX
EV/FCFXXX(7.0x)XXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Genxone Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Genxone Margins & Growth Rates

Genxone's revenue in the last fiscal year grew by 31%.

See operational valuation multiples for Genxone and other 15K+ public comps

Genxone Operational Valuation Multiples

LTMNTMLast FYFY 2026FY 2027FY 2028
Revenue GrowthXXX31%XXXXXXXXX
EBITDA MarginXXX(47%)XXXXXXXXX
EBITDA GrowthXXX(57%)XXXXXXXXX
Opex to RevenueXXX158%XXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Genxone Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

EV/RevenueEV/EBITDA
LTM2026E2027ELTM2026E2027E
GenxoneXXXXXXXXXXXXXXXXXX
AtonXXXXXXXXXXXXXXXXXX
Modus TherapeuticsXXXXXXXXXXXXXXXXXX
Instituto RosenbuschXXXXXXXXXXXXXXXXXX
Akari TherapeuticsXXXXXXXXXXXXXXXXXX
Institute of BiomedicalXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX

Valuation data powered by FactSet, Inc.

Genxone M&A Activity

Genxone acquired XXX companies to date.

Last acquisition by Genxone was on XXXXXXXX, XXXXX. Genxone acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See M&A valuation multiples

Latest Acquisitions by Genxone

Acquired CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.

Start Free Trial

Genxone Investment Activity

Genxone invested in XXX companies to date.

Genxone made its latest investment on XXXXXXXX, XXXXX. Genxone invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See VC round multiples

Latest Investments by Genxone

CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Genxone

When was Genxone founded?Genxone was founded in 2016.
Where is Genxone headquartered?Genxone is headquartered in Poland.
Is Genxone publicly listed?Yes, Genxone is a public company listed on Warsaw Stock Exchange.
What is the stock symbol of Genxone?Genxone trades under GX1 ticker.
When did Genxone go public?Genxone went public in 2020.
Who are competitors of Genxone?Genxone main competitors are Aton, Modus Therapeutics, Instituto Rosenbusch, Akari Therapeutics.
What is the current market cap of Genxone?Genxone's current market cap is $6M.
What is the current revenue of Genxone?Genxone's last fiscal year revenue is $653K.
What is the current EV/Revenue multiple of Genxone?Current revenue multiple of Genxone is 7.4x.
Is Genxone profitable?No, Genxone is not profitable.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial